US lawmakers want answers on excessive off-label antipsychotic use in nursing homes
This article was originally published in Scrip
Executive Summary
Two US senators want the Centers for Medicare & Medicaid Services (CMS) to explain what the agency is doing to safeguard nursing home residents from unnecessary treatment with antipsychotics after government investigators reported that 83% of the use of those drugs in that population is done off-label, or for uses not approved by the US FDA.